Hypersensitivity reactions are reported in approximately 5% of adults receiving abacavir, but there are few published data in children. Among 1150 children in Uganda and Zimbabwe receiving antiretroviral therapy for HIV in a randomized trial, suspected hypersensitivity reactions to abacavir were rare (0.3%; 95% CI, 0.01-0.9). Patients were managed successfully through the provision of clear guidelines and education of clinical staff, children, and their caregivers.
The Pediatric Infectious Disease Journal (2010), published online before print, 15 December 2010 [doi:10.1097/INF.0b013e3182076864]
Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy.